Biolase Q3 2023 Gaap EPS $(3.89) Misses $(1.85) Estimate, Sales $10.92M Miss $13.96M Estimate
Portfolio Pulse from saritha@benzinga.com
Biolase reported Q3 2023 GAAP EPS of $(3.89), missing the estimate of $(1.85) by 110.27%. This is a 96.46% increase over losses from the same period last year. The company also reported quarterly sales of $10.92M, missing the estimate of $13.96M by 21.77%, a 9.07% decrease from the same period last year.
November 09, 2023 | 10:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biolase's Q3 2023 earnings and sales missed estimates, indicating a potential negative impact on the stock.
Biolase's earnings per share and sales for Q3 2023 both missed estimates, which could lead to a decrease in investor confidence and a potential drop in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100